New peanut allergy vaccine enters human testing – could it end the danger?
NCT ID NCT05476497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new vaccine called VLP Peanut in 46 healthy adults and people with peanut allergy. The goal is to see if it is safe and tolerable, and to get an early look at whether it might reduce allergic reactions. Participants receive injections of the vaccine or a placebo, and researchers monitor side effects and immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VLP Peanut (a virus-like particle vaccine designed to desensitize the immune system to peanut proteins)
What this could lead to
If successful, this could lead to a treatment that reduces or eliminates severe allergic reactions to peanuts, allowing patients to tolerate accidental exposure.
What could go wrong
This is an early Phase 1 trial with only 46 participants, focused on safety. The vaccine may cause allergic reactions or prove ineffective in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Trio Clinical Trials, LLC.
Houston, Texas, 77008, United States
-
University of Arizona
Tucson, Arizona, 85724, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of South Florida
Tampa, Florida, 33613, United States
-
University of Wisconsin School of Medicine and Public Health Asthma, Allergy, and Pulmonary Clinical Research
Madison, Wisconsin, 53792-9988, United States
-
Washington University School of Medicine
St Louis, Missouri, 63141, United States